 Lyle Burdine
Concepts (189)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA-Activated Protein Kinase | 5 | 2024 | 26 | 1.310 |
Why?
| | Liver Transplantation | 7 | 2024 | 150 | 1.180 |
Why?
| | Kidney Transplantation | 4 | 2022 | 177 | 1.160 |
Why?
| | Graft Survival | 7 | 2022 | 151 | 0.970 |
Why?
| | Cholecystectomy | 1 | 2021 | 29 | 0.750 |
Why?
| | Bile Ducts | 1 | 2021 | 45 | 0.740 |
Why?
| | Postoperative Care | 1 | 2021 | 102 | 0.720 |
Why?
| | Organ Transplantation | 1 | 2020 | 47 | 0.700 |
Why?
| | Patient Readmission | 1 | 2021 | 218 | 0.660 |
Why?
| | Interleukin-2 | 1 | 2017 | 72 | 0.580 |
Why?
| | Calcineurin | 1 | 2017 | 73 | 0.540 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2015 | 24 | 0.500 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2015 | 33 | 0.490 |
Why?
| | Thyroid Neoplasms | 1 | 2015 | 111 | 0.450 |
Why?
| | Nuclear Proteins | 1 | 2015 | 243 | 0.450 |
Why?
| | Chromones | 2 | 2024 | 20 | 0.430 |
Why?
| | Morpholines | 2 | 2024 | 70 | 0.410 |
Why?
| | Proteomics | 1 | 2015 | 327 | 0.410 |
Why?
| | Tissue and Organ Procurement | 2 | 2022 | 40 | 0.380 |
Why?
| | Cold Ischemia | 2 | 2022 | 9 | 0.370 |
Why?
| | Delayed Graft Function | 2 | 2022 | 10 | 0.370 |
Why?
| | Peptides | 4 | 2009 | 223 | 0.370 |
Why?
| | Graft Rejection | 2 | 2022 | 169 | 0.360 |
Why?
| | DNA-Binding Proteins | 4 | 2021 | 428 | 0.340 |
Why?
| | Dihydroxyphenylalanine | 3 | 2006 | 5 | 0.330 |
Why?
| | Periodic Acid | 2 | 2006 | 3 | 0.310 |
Why?
| | Cross-Linking Reagents | 5 | 2008 | 43 | 0.310 |
Why?
| | Saccharomyces cerevisiae Proteins | 3 | 2008 | 154 | 0.290 |
Why?
| | Humans | 24 | 2024 | 50251 | 0.290 |
Why?
| | Tissue Donors | 4 | 2022 | 113 | 0.290 |
Why?
| | Phosphorylation | 2 | 2017 | 534 | 0.240 |
Why?
| | Receptors, Drug | 1 | 2004 | 4 | 0.240 |
Why?
| | Solubility | 1 | 2024 | 72 | 0.240 |
Why?
| | Hepatic Artery | 1 | 2024 | 20 | 0.240 |
Why?
| | Thrombectomy | 1 | 2024 | 68 | 0.230 |
Why?
| | Transplants | 1 | 2023 | 19 | 0.220 |
Why?
| | Repressor Proteins | 1 | 2004 | 153 | 0.220 |
Why?
| | Transcriptional Activation | 2 | 2017 | 121 | 0.220 |
Why?
| | Retrospective Studies | 7 | 2024 | 6172 | 0.220 |
Why?
| | T-Lymphocytes | 2 | 2024 | 339 | 0.210 |
Why?
| | Antibody Formation | 1 | 2022 | 51 | 0.210 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 207 | 0.210 |
Why?
| | Middle Aged | 7 | 2024 | 12234 | 0.210 |
Why?
| | Creatinine | 1 | 2022 | 142 | 0.200 |
Why?
| | Cholecystitis | 1 | 2021 | 12 | 0.200 |
Why?
| | Hospitals, Low-Volume | 1 | 2021 | 16 | 0.200 |
Why?
| | Cholecystostomy | 1 | 2021 | 8 | 0.200 |
Why?
| | Hospitals, High-Volume | 1 | 2021 | 25 | 0.200 |
Why?
| | Cholecystitis, Acute | 1 | 2021 | 9 | 0.200 |
Why?
| | Jurkat Cells | 2 | 2021 | 29 | 0.200 |
Why?
| | Protein Stability | 2 | 2021 | 45 | 0.190 |
Why?
| | Early Growth Response Protein 1 | 1 | 2021 | 35 | 0.190 |
Why?
| | Databases as Topic | 1 | 2021 | 37 | 0.190 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2021 | 19 | 0.190 |
Why?
| | Stents | 1 | 2024 | 345 | 0.190 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 171 | 0.190 |
Why?
| | Skin Transplantation | 1 | 2021 | 44 | 0.180 |
Why?
| | Graft vs Host Disease | 1 | 2020 | 75 | 0.170 |
Why?
| | Immunocompromised Host | 1 | 2020 | 119 | 0.170 |
Why?
| | Female | 9 | 2024 | 26668 | 0.170 |
Why?
| | Wounds and Injuries | 1 | 2022 | 280 | 0.170 |
Why?
| | Warm Ischemia | 1 | 2018 | 3 | 0.160 |
Why?
| | Reoperation | 1 | 2021 | 456 | 0.160 |
Why?
| | Tissue and Organ Harvesting | 1 | 2018 | 23 | 0.160 |
Why?
| | Hepatectomy | 1 | 2018 | 22 | 0.160 |
Why?
| | United States | 4 | 2022 | 4887 | 0.160 |
Why?
| | Central Venous Pressure | 1 | 2018 | 7 | 0.160 |
Why?
| | Operative Time | 1 | 2018 | 73 | 0.160 |
Why?
| | Living Donors | 1 | 2018 | 23 | 0.150 |
Why?
| | Intraoperative Care | 1 | 2018 | 54 | 0.150 |
Why?
| | NFATC Transcription Factors | 1 | 2017 | 23 | 0.150 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2017 | 34 | 0.150 |
Why?
| | Male | 7 | 2024 | 25483 | 0.150 |
Why?
| | End Stage Liver Disease | 1 | 2018 | 47 | 0.150 |
Why?
| | Monitoring, Physiologic | 1 | 2018 | 120 | 0.140 |
Why?
| | Renal Insufficiency | 1 | 2018 | 109 | 0.140 |
Why?
| | Renal Dialysis | 1 | 2018 | 169 | 0.140 |
Why?
| | Oligopeptides | 1 | 2017 | 91 | 0.140 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 1418 | 0.140 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 170 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2018 | 200 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 567 | 0.130 |
Why?
| | Gene Expression | 1 | 2017 | 615 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2023 | 1186 | 0.120 |
Why?
| | Treatment Outcome | 5 | 2024 | 5186 | 0.110 |
Why?
| | Aged | 3 | 2024 | 9427 | 0.110 |
Why?
| | DNA | 3 | 2023 | 542 | 0.100 |
Why?
| | Indoles | 1 | 2015 | 279 | 0.100 |
Why?
| | Death | 2 | 2022 | 21 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 828 | 0.090 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 306 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2005 | 587 | 0.080 |
Why?
| | Cholera Toxin | 1 | 2009 | 15 | 0.080 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 793 | 0.080 |
Why?
| | Quinones | 2 | 2006 | 8 | 0.080 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2008 | 117 | 0.080 |
Why?
| | Ubiquitin | 1 | 2008 | 45 | 0.080 |
Why?
| | Signal Transduction | 1 | 2015 | 1624 | 0.080 |
Why?
| | Intestinal Mucosa | 1 | 2009 | 215 | 0.080 |
Why?
| | Mice | 3 | 2023 | 5770 | 0.070 |
Why?
| | Peptide Nucleic Acids | 1 | 2006 | 17 | 0.070 |
Why?
| | Wiskott-Aldrich Syndrome Protein, Neuronal | 1 | 2005 | 1 | 0.070 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2005 | 2 | 0.070 |
Why?
| | Bacterial Proteins | 1 | 2009 | 376 | 0.060 |
Why?
| | Liver | 2 | 2022 | 1119 | 0.060 |
Why?
| | Risk Factors | 3 | 2018 | 3608 | 0.060 |
Why?
| | Time Factors | 2 | 2024 | 2911 | 0.060 |
Why?
| | Proteins | 1 | 2007 | 345 | 0.060 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2004 | 10 | 0.060 |
Why?
| | Genetic Techniques | 1 | 2004 | 14 | 0.060 |
Why?
| | Suction | 1 | 2024 | 24 | 0.060 |
Why?
| | Chromatography, Affinity | 1 | 2004 | 38 | 0.060 |
Why?
| | Biosensing Techniques | 1 | 2004 | 26 | 0.060 |
Why?
| | Vascular Patency | 1 | 2024 | 82 | 0.060 |
Why?
| | Animals | 4 | 2023 | 13285 | 0.060 |
Why?
| | Radiography, Interventional | 1 | 2024 | 57 | 0.060 |
Why?
| | Oxidation-Reduction | 1 | 2004 | 322 | 0.050 |
Why?
| | Social Class | 1 | 2023 | 94 | 0.050 |
Why?
| | DNA Damage | 1 | 2024 | 301 | 0.050 |
Why?
| | Protein Binding | 3 | 2009 | 668 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 127 | 0.050 |
Why?
| | Resuscitation | 1 | 2022 | 73 | 0.050 |
Why?
| | Transcription Factors | 1 | 2005 | 564 | 0.050 |
Why?
| | Waiting Lists | 1 | 2021 | 53 | 0.050 |
Why?
| | Adult | 3 | 2024 | 13384 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 163 | 0.050 |
Why?
| | Endovascular Procedures | 1 | 2024 | 176 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 96 | 0.050 |
Why?
| | Blood Transfusion | 1 | 2022 | 131 | 0.050 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 580 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 177 | 0.050 |
Why?
| | Thrombosis | 1 | 2024 | 249 | 0.050 |
Why?
| | Trauma Centers | 1 | 2022 | 193 | 0.050 |
Why?
| | Brain Death | 1 | 2021 | 18 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2021 | 106 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2022 | 455 | 0.050 |
Why?
| | Hemorrhage | 1 | 2022 | 197 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2021 | 69 | 0.050 |
Why?
| | Nitriles | 1 | 2020 | 54 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2023 | 270 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2021 | 370 | 0.040 |
Why?
| | Pyrazoles | 1 | 2020 | 115 | 0.040 |
Why?
| | Incidence | 1 | 2022 | 986 | 0.040 |
Why?
| | Primary Graft Dysfunction | 1 | 2018 | 3 | 0.040 |
Why?
| | Pyrimidines | 1 | 2020 | 194 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2018 | 47 | 0.040 |
Why?
| | Registries | 1 | 2021 | 513 | 0.040 |
Why?
| | Hyperkalemia | 1 | 2018 | 11 | 0.040 |
Why?
| | Cytokines | 1 | 2021 | 615 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2021 | 478 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2018 | 49 | 0.040 |
Why?
| | Length of Stay | 1 | 2021 | 627 | 0.040 |
Why?
| | Decision Support Techniques | 1 | 2018 | 71 | 0.040 |
Why?
| | Acidosis | 1 | 2018 | 40 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2018 | 110 | 0.040 |
Why?
| | Perioperative Care | 1 | 2018 | 42 | 0.040 |
Why?
| | Propensity Score | 1 | 2018 | 121 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 914 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 1470 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 1823 | 0.030 |
Why?
| | Risk Assessment | 1 | 2018 | 1257 | 0.030 |
Why?
| | Cohort Studies | 1 | 2018 | 1397 | 0.030 |
Why?
| | Kidney | 1 | 2018 | 672 | 0.030 |
Why?
| | Prognosis | 1 | 2018 | 1959 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2018 | 2180 | 0.030 |
Why?
| | Peptide Library | 1 | 2009 | 16 | 0.020 |
Why?
| | Protein Subunits | 1 | 2009 | 78 | 0.020 |
Why?
| | Ligands | 1 | 2009 | 204 | 0.020 |
Why?
| | Bacterial Infections | 1 | 2009 | 95 | 0.020 |
Why?
| | Hydrolysis | 1 | 2008 | 62 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2008 | 75 | 0.020 |
Why?
| | Models, Chemical | 1 | 2008 | 64 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2008 | 87 | 0.020 |
Why?
| | Escherichia coli | 1 | 2009 | 189 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 261 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 2008 | 189 | 0.020 |
Why?
| | Molecular Structure | 1 | 2007 | 296 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 63 | 0.020 |
Why?
| | Cell Line | 1 | 2009 | 1024 | 0.020 |
Why?
| | Actin-Related Protein 3 | 1 | 2005 | 1 | 0.020 |
Why?
| | Photochemistry | 1 | 2005 | 16 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2005 | 30 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2005 | 58 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2006 | 327 | 0.020 |
Why?
| | Cattle | 1 | 2005 | 218 | 0.020 |
Why?
| | Binding Sites | 1 | 2005 | 375 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 363 | 0.010 |
Why?
| | Models, Molecular | 1 | 2005 | 342 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 1296 | 0.010 |
Why?
|
|
Burdine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|